Shinya Ikeda
Research Subjects
Shinya Ikeda has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Eiichiro Nishi
Department of Pharmacology, Shiga University of Medical Science, Otsu, Japan
3 shared publications - Hirotaka Iwasaki
Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
3 shared publications - Kiyoto Nishi
Shiga University of Medical Science, Japan
3 shared publications - Mend Amar Batbaatar
Department of Pharmacology, Seta Tsukinowa-cho, Otsu, Shiga, 520-2192, Japan; Department of Pharmacology, School of Bio-Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia
3 shared publications Narangerel Ganbaatar
3 shared publicationsYukihito Sato
Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JPN
3 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 47
Nardilysin regulates Slc2a2 expression via an ISLET1-dependent enhancer mechanism in pancreatic β-cells
- 2 September 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 47
Open AccessNardilysin regulates Slc2a2 expression via an ISLET1-dependent enhancer mechanism in pancreatic β-cells
- Open Access
- 7 May 2026
- Published by Elsevier in SSRN Electronic Journal
Identification of a small-molecule inhibitor of nardilysin and its pharmacological effects on transcriptional regulation and inflammatory arthritis
Nardilysin (NRDC) is a zinc metallopeptidase of the M16 family that participates in diverse biological processes, including ectodomain shedding and antigen processing. NRDC also functions as a transcriptional coregulator, and this coregulatory activity depends on its metallopeptidase catalytic function. However, small-molecule inhibitors targeting NRDC have not been well characterized, limiting pharmacological investigation of its enzymatic function.Here we established a fluorescence-quenched peptide substrate assay suitable for high-throughput screening of NRDC protease activity. Using this assay, we screened 33,305 compounds and identified 140 candidate NRDC inhibitors. Through secondary screening, orthogonal validation and structure–activity relationship analysis, three inhibitor scaffolds were identified, from which compound R5-1 was selected for further characterization. Enzyme kinetic analysis demonstrated that R5-1 inhibits NRDC activity in a non-competitive manner, indicating reduced catalytic turnover rather than direct competition with substrate binding. Structural modeling and docking analysis further suggested that R5-1 binds to a distal allosteric site in NRDC.Pharmacological inhibition of NRDC with R5-1 attenuated NRDC-dependent transcriptional repression of PGC-1α, phenocopying the effect of catalytic inactivation. Furthermore, administration of R5-1 significantly ameliorated arthritis severity in a mouse model of autoimmune arthritis. Together, these findings identify R5-1 as a small-molecule inhibitor of NRDC and provide mechanistic insights linking NRDC protease activity to transcriptional regulation and inflammatory disease.
- 7 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIdentification of a small-molecule inhibitor of nardilysin and its pharmacological effects on transcriptional regulation and inflammatory arthritis
Nardilysin (NRDC) is a zinc metallopeptidase of the M16 family that participates in diverse biological processes, including ectodomain shedding and antigen processing. NRDC also functions as a transcriptional coregulator, and this coregulatory activity depends on its metallopeptidase catalytic function. However, small-molecule inhibitors targeting NRDC have not been well characterized, limiting pharmacological investigation of its enzymatic function.Here we established a fluorescence-quenched peptide substrate assay suitable for high-throughput screening of NRDC protease activity. Using this assay, we screened 33,305 compounds and identified 140 candidate NRDC inhibitors. Through secondary screening, orthogonal validation and structure–activity relationship analysis, three inhibitor scaffolds were identified, from which compound R5-1 was selected for further characterization. Enzyme kinetic analysis demonstrated that R5-1 inhibits NRDC activity in a non-competitive manner, indicating reduced catalytic turnover rather than direct competition with substrate binding. Structural modeling and docking analysis further suggested that R5-1 binds to a distal allosteric site in NRDC.Pharmacological inhibition of NRDC with R5-1 attenuated NRDC-dependent transcriptional repression of PGC-1α, phenocopying the effect of catalytic inactivation. Furthermore, administration of R5-1 significantly ameliorated arthritis severity in a mouse model of autoimmune arthritis. Together, these findings identify R5-1 as a small-molecule inhibitor of NRDC and provide mechanistic insights linking NRDC protease activity to transcriptional regulation and inflammatory disease.
- Open Access
- 5 March 2026
- Published by Elsevier in SSRN Electronic Journal
Nardilysin regulates Slc2a2 expression through ISLET1 recruitment to an evolutionarily conserved enhancer in pancreatic β-cells
GLUT2 (Slc2a2) is a key glucose transporter in pancreatic β-cells, and its reduced expression is closely linked to defective glucose-stimulated insulin secretion (GSIS) and diabetes. We previously reported that pancreatic β-cell–specific nardilysin (NRDC)-deficient mice (BetaKO) exhibit severe diabetic phenotype with defective GSIS and reduced Slc2a2 expression in islets. However, because BetaKO mice also showed reduced MafA, a key upstream regulator of Slc2a2, along with an increased α-cell/β-cell ratio and other secondary changes that could influence GLUT2 levels, the mechanism by which NRDC regulates Slc2a2 transcription remained unclear. Here, we demonstrate that NRDC controls Slc2a2 expression in a β-cell autonomous and MafA-independent manner. By integrating publicly available ATAC-seq and ChIP-seq datasets, we identified four active enhancer regions around the murine Slc2a2 locus, two of which are evolutionarily conserved in human islets. Luciferase assays revealed that NRDC selectively controls the activity of a conserved enhancer located 39k bp downstream of the Slc2a2 transcriptional start site. Chromatin immunoprecipitation (ChIP) and re-ChIP assays further revealed that NRDC binds to this enhancer and is required for efficient recruitment of ISLET1, a transcription factor upstream of Slc2a2. These findings indicate that NRDC directly regulates Slc2a2 in addition to MafA, highlighting multifaceted roles of NRDC in pancreatic β-cell gene regulation.
- 5 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNardilysin regulates Slc2a2 expression through ISLET1 recruitment to an evolutionarily conserved enhancer in pancreatic β-cells
GLUT2 (Slc2a2) is a key glucose transporter in pancreatic β-cells, and its reduced expression is closely linked to defective glucose-stimulated insulin secretion (GSIS) and diabetes. We previously reported that pancreatic β-cell–specific nardilysin (NRDC)-deficient mice (BetaKO) exhibit severe diabetic phenotype with defective GSIS and reduced Slc2a2 expression in islets. However, because BetaKO mice also showed reduced MafA, a key upstream regulator of Slc2a2, along with an increased α-cell/β-cell ratio and other secondary changes that could influence GLUT2 levels, the mechanism by which NRDC regulates Slc2a2 transcription remained unclear. Here, we demonstrate that NRDC controls Slc2a2 expression in a β-cell autonomous and MafA-independent manner. By integrating publicly available ATAC-seq and ChIP-seq datasets, we identified four active enhancer regions around the murine Slc2a2 locus, two of which are evolutionarily conserved in human islets. Luciferase assays revealed that NRDC selectively controls the activity of a conserved enhancer located 39k bp downstream of the Slc2a2 transcriptional start site. Chromatin immunoprecipitation (ChIP) and re-ChIP assays further revealed that NRDC binds to this enhancer and is required for efficient recruitment of ISLET1, a transcription factor upstream of Slc2a2. These findings indicate that NRDC directly regulates Slc2a2 in addition to MafA, highlighting multifaceted roles of NRDC in pancreatic β-cell gene regulation.
- 16 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 712-713, 149961
Nardilysin in vascular smooth muscle cells controls blood pressure via the regulation of calcium dynamics
- 16 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 712-713, 149961
Nardilysin in vascular smooth muscle cells controls blood pressure via the regulation of calcium dynamics
- Open Access
- 9 December 2023
- Published by Springer Nature in Cureus
- Vol. 15 (12) , e50244
Rupture of Non-aneurysmal Mycotic Thoracic Aortic Arteritis Caused by Campylobacter fetus
Campylobacter fetus (C. fetus) demonstrates a preference for vascular tissue and is an infrequent etiology of mycotic aortic arteritis (MAA), mostly occurring in the abdominal aorta. MAA characteristically has a rapid progression to aneurysm formation and subsequently, to aortic rupture. We present a 73-year-old woman with non-aneurysmal mycotic thoracic aortic arteritis (MTAA) complicated with a rupture caused by C. fetus. She presented after four days of pain in the lower abdomen. Contrast-enhanced computed tomography revealed non-aneurysmal descending thoracic aorta arteritis and an abdominal aorta aneurysm, and the blood cultures were positive for C. fetus. Antibiotic therapy relieved the abdominal pain. However, eight days after the antibiotic therapy, she died because of a rupture of the non-aneurysmal MTAA. The non-aneurysmal MTAA caused by C. fetus ruptured while the infection was being treated with appropriate antibiotics, and there was no sign of arterial dilatation. An early open or endovascular repair after a short pre-operative antibiotic therapy may be required for non-aneurysmal MAA caused by C. fetus. More cases of non-aneurysmal MAA caused by C. fetus are needed to determine the clinical course and to decide the treatment strategy.
- 9 December 2023
- Published by Springer Nature in Cureus
- Vol. 15 (12) , e50244
Open AccessRupture of Non-aneurysmal Mycotic Thoracic Aortic Arteritis Caused by Campylobacter fetus
Campylobacter fetus (C. fetus) demonstrates a preference for vascular tissue and is an infrequent etiology of mycotic aortic arteritis (MAA), mostly occurring in the abdominal aorta. MAA characteristically has a rapid progression to aneurysm formation and subsequently, to aortic rupture. We present a 73-year-old woman with non-aneurysmal mycotic thoracic aortic arteritis (MTAA) complicated with a rupture caused by C. fetus. She presented after four days of pain in the lower abdomen. Contrast-enhanced computed tomography revealed non-aneurysmal descending thoracic aorta arteritis and an abdominal aorta aneurysm, and the blood cultures were positive for C. fetus. Antibiotic therapy relieved the abdominal pain. However, eight days after the antibiotic therapy, she died because of a rupture of the non-aneurysmal MTAA. The non-aneurysmal MTAA caused by C. fetus ruptured while the infection was being treated with appropriate antibiotics, and there was no sign of arterial dilatation. An early open or endovascular repair after a short pre-operative antibiotic therapy may be required for non-aneurysmal MAA caused by C. fetus. More cases of non-aneurysmal MAA caused by C. fetus are needed to determine the clinical course and to decide the treatment strategy.
- 5 November 2022
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 109, 135-137
Impact of chronic lung disease on long-term clinical outcomes in patients with venous thromboembolism: From the COMMAND VTE registry
- 5 November 2022
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 109, 135-137
Impact of chronic lung disease on long-term clinical outcomes in patients with venous thromboembolism: From the COMMAND VTE registry
- 6 June 2019
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 35 (3) , 310-312
A percutaneous intravascular cracking (PICKING) with a TruePath™ for extremely calcified lesions
- 6 June 2019
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 35 (3) , 310-312
A percutaneous intravascular cracking (PICKING) with a TruePath™ for extremely calcified lesions